Abstract The spindle assembly checkpoint is a cell cycle surveillance mechanism that ensures the proper separation of chromosomes prior to cell division at mitosis. Aurora kinases play critical roles in mitotic progression and hence small-molecule inhibitors of Aurora kinases have been developed as a new class of potential anticancer drugs. In this paper we present for the first time an integrated pharmacokinetic-pharmacodynamic model of the functional effects of CYC116 (a known inhibitor of Aurora kinases A and B) on the spindle assembly checkpoint. We use the model to simulate two common experimental systems: cell culture and p.o. dosing of mice and present predictions of the effects of CYC116 for a range of doses and drug scheduling regimes. The model reveals that a critical peak drug concentration is required to cause aberrant kinetochore-microtubule attachments. The model also predicts that provided this threshold concentration is exceeded, a high total oral dose causes a high number of aberrant attachments within any given damaged cell. However, the proportion of cells which enter anaphase with aberrant attachments is associated with the total length of time for which the plasma concentration is maintained above the threshold. Moreover, our model reveals that the length of prometaphase/metaphase is a nonlinear function of drug dose and this time period can be extended or shortened. Finally, a strong saturation effect on CYC116 efficacy is predicted by the model. We discuss how these predictions may have implications for further drug trials using CYC116 and other similar AK inhibitors.
Introduction
The spindle assembly checkpoint (SAC)
The spindle assembly checkpoint (SAC) is the major cell cycle control mechanism in mitosis. It is responsible for the production of genetically identical daughter cells by ensuring accurate chromosome segregation. This checkpoint is crucial to prevent onset of anaphase without proper alignment of chromosomes and correctly attached spindles. Unattached kinetochores generate diffusible checkpoint complexes that comprise a wait signal, which inhibits the activation of the anaphase-promoting complex/cyclosome (APC/C) and delays the irreversible transition from metaphase to anaphase until all kinetochores become appropriately attached. Even one unattached kinetochore is considered to be enough to prevent the onset of anaphase [1, 2, 3, 4] .
At a molecular level, the spindle assembly checkpoint prevents advance to anaphase by inhibiting Cdc20, which is an activator of APC/C. It is unclear how the spindle assembly checkpoint inactivates Cdc20, however, a possible mechanism is as follows (see [5] for more details). The APC/C becomes active when it binds the activator Cdc20. Unattached kinetochores recruit checkpoint proteins. These checkpoint proteins prevent Cdc20 from activating APC/C by causing a conformational change. These inhibited forms of Cdc20 are assumed to be able to catalyse the production of further inhibited complexes of Cdc20, which are different in that they cannot themselves act as catalysts. This type of signal amplification ensures that the inhibitory signal is only amplified by molecules that interact with an unattached kinetochore. Although not considered in this paper, as well as the inhibition of Cdc20 through checkpoint proteins, a second mode of Cdc20 inhibition due to its degradation mediated by the APC/C is suggested [6, 7] . Once all kinetochores have properly attached, signal generation is silenced and the inhibitors of Cdc20 decay rapidly. This activates APC/C and the cell cycle progresses to anaphase.
Aurora kinases and cancer
It is thought that the Aurora kinases are centrally involved throughout the cell cycle but they exhibit most of their known functions in mitosis. Aurora has evolved into three related kinases known as Aurora A, Aurora B, and Aurora C (hereafter AK-A, AK-B and AK-C, respectively) (reviewed in ref. [8] ). They are involved in some checkpoint regulation pathways including spindle assembly checkpoint, alignment of metaphase chromosomes, chromosomal biorientation, kinetochore-microtubule association and cytokinesis [9] . Aberrant expression of Aurora kinases may disturb checkpoint functions particularly in mitosis and this may lead to deregulation of cell division and trigger the development of tumours [10, 11] . Indeed Aurora kinases are over-expressed in a number of cancers, and transfection studies have established AK-A as a bone fide oncogene [12, 13, 14, 15] . Overexpression of AK-B also induces tumour formation [16, 17] . AK-C has been found to be over-expressed in some cancer cell lines including HepG2, HUH7, MDA-MB-453 and HeLa. However, its correlation with cancer progression is unclear [18] .
The aberrant expression of Aurora kinases appears to be a common feature in a wide class of cancers. This contrasts with other oncogenic kinases, which are more selectively affected. Hence, Aurora kinase inhibitors have the potential to target a wide range of tumour types, and therefore are currently attracting significant interest. Indeed, several small-molecule inhibitors of Aurora kinases have been developed as a new class of potential anti-cancer drugs (e.g. Hesperadin, ZM447439, MK0457 previously VX-680, PHA-680632, AZD1152, MLN8054, CYC116, in ref. [19] ). These AK inhibitors can be subdivided into three general classes: those that have selectivity for AK-A over AK-B, those with selectivity for AK-B over AK-A, and those that are potent inhibitors of both AK-A and AK-B. So far it is not clear whether these alternative selectivity profiles will confer differences in the clinic.
Modelling the dynamic effects of drug dose on multi-cellular populations: a novel integrated approach
The aim of this work is to better understand the action of AK inhibitors in order to accelerate their development towards effective anti-cancer agents. In this paper, we considered the compound CYC116 ( [19, 20] ). It has previously been shown that CYC116 inhibits both AK-A and AK-B and it is thought that its main cite of action is the spindle assembly checkpoint. However, at present, no quantitative link between dose size, dose frequency and efficacy of treatment has been established. We believe that such a link will accelerate drug trials of this and similar compounds and ultimately allow for the development of more patient-specific treatment. In order to gain a better insight into the complex interplay between pharmacokinetics, measurable biomarkers and cell fate required the construction of a novel integrated mathematical model, which we present here. This model builds on the core SAC models developed in [21, 22] . To the authors' best knowledge, these were the first such models to be used to investigate the action of AK inhibition on the spindle assembly checkpoint, albeit from a functional point of view in which the source of inhibition was not explicitly detailed. The new, integrated PK-PD model presented here attempts to complete the link between drug dose and drug effect. It is capable of tracking the effect of single and multiple drug doses on multiple cohorts of cells as each of these cohorts passes through prometaphase/metaphase during a 24 h period. Therefore this new model is not only capable of predicting ''total cell damage'' in a whole generation of cells, but also the nature and distribution of chromosomal defects and how these vary with different total dose and dosing regime.
The paper is structured as follows. We first describe the model construction by briefly reviewing the attachment and spindle assembly checkpoint models developed in [21, 22] . We then discuss the inhibition of AK activity by CYC116 and thus the effects of such inhibition on parameters in the new integrated PK-PD model presented here. Simulations of two common laboratory systems: cell culture and tumour-bearing mice are presented and in the final section, results from these comparative studies are discussed.
Model construction
Kinetochore-microtubule attachment A human cell contains 23 pairs of chromosomes (for future reference, a mouse cell contains 20 pairs), which are duplicated during mitosis, resulting in 46 pairs of chromosomes, each with two kinetochores. Each kinetochore is known to have 20-30 microtubule binding sites. Proper chromosome segregation requires sister kinetochores to form an amphitelic attachment, where two sister kinetochores are bound to microtubules from opposite spindle poles. However, three types of incorrect attachments can occur that lead to a miss-segregation of chromosomes: (i) unattached; (ii) syntelic (both sister kinetochores are bound to microtubules from the same pole); (iii) merotelic (one sister kinetochore is bound to microtubules from both spindle poles), see Fig. 1a . A model of the temporal evolution of attachment type was developed in [21] and full details of the derivation can be found there. A brief overview of the main points follows. A pair of sister kinetochores is defined as a unit and it is assumed that both kinetochores within the unit have all their binding sites occupied or both kinetochores have binding sites available. Moreover, it is assumed that these two sets can be divided as follows: a unit displaying full occupancy can be in either a merotelic (ME) or amphitelic (C) state; otherwise it is deemed to be in a syntelic (S) or unattached (U) state. Thus a unit state transition network can be constructed as in Fig. 1b . This forms the core framework of the model for the microtubule attachment process. How this transition process is mediated by AK inhibition is discussed below.
Spindle checkpoint model
The spindle assembly checkpoint model, proposed in [5] and subsequently extended in [21] , concerns the wait signal generated by the temporal evolution of kinetochore-microtubule attachments. A brief summary of this model is as follows. A species denoted by e is associated with free Cdc20. Both U and S units can generate inhibited complexes of e, denoted by e * with a possible candidate being the Cdc20-Mad2 complex, at a diffusion limited rate, k k . It is assumed that the inhibited complex e * can catalyse the production of further inhibited complexes of e denoted by c * with a possible candidate being the Cdc20-BubR1 complex, at a diffusion limited protein-protein interaction rate, k. It is assumed that these complexes, c * , cannot catalyse further complexation. Species g * is associated with inhibitory complexes of Cdc20 generated prior to prometaphase and by a different mechanism during prophase [21] . These inhibitory complexes decay releasing the Cdc20 at rate a. The reaction processes are summarised as 
Aurora kinase activity and CYC116
The levels of active Aurora kinases are normally calculated by analysing the concentration of kinase-specific biomarkers. Biomarkers identified for AK-A and AK-B are phosphorylated Aurora kinase A and phosphorylated histone H3, respectively [23, 24, 25] . We will make use of these relationships.
To model the level of AK activity, we employ the following argument. Denote the concentration of CYC116 by [CYC116] and let the relative concentration of the biomarker phosphorylated AK-A be denoted by A p (that is the concentration divided by the concentration measured when no inhibitor is present). Next, let A denote the relative activity of AK-A. Then A [ [0, 1] with A = 0 and A = 1 representing the fully inhibited and uninhibited cases, respectively. The standard assumption is that A = A p , that is the relative concentration of the biomarker can be used as a surrogate for relative activity (see e.g. [26, 27] ). Thus and again using standard arguments (see e.g. [28] ), the relative activity A is related to [CYC116] by
where n is the Hill constant and IC A 50 is the concentration of CYC116 required to reduce relative concentration by 50%. We assume that a corresponding relationship holds between AK-B activity and the relative concentration of its biomarker phosphorylated histone H3, with the obvious notational changes.
The IC 50 values for AK-A and AK-B, are calculated using the Cheng-Prusoff equation for competitive inhibitors [29] , viz.
where K ia and K ib are the inhibitor dissociation constants for AK-A and AK-B, respectively, [ATP] is the cellular concentration of ATP and K ma and K mb are the Michaelis constants of AK-A and AK-B, respectively. The experimental data was used to estimate the Hill constant n for AK activity. The Hill constant n = 1 gives the minimum least square errors for both AK-A and AK-B and the fitted curves along with the data are shown in Fig. 2a Effect of Aurora kinase inhibition on rate constants AK-A is involved in mitotic entry, separation of centriole pairs, accurate bipolar spindle assembly, and alignment of metaphase chromosomes and completion of cytokinesis [30] . The role of AK-A in the promotion of nuclear envelop breakdown has also been described [31] . Depletion of AK-A, in cells that contained a correct bipolar spindle structure, resulted in a checkpoint dependent prolonged mitosis caused by unstable kinetochore-microtubule attachments [32] . Incorrect kinetochore-microtubule attachments can be resolved by AK-B [33] : if either a merotelic or syntelic attachment occurs, AK-B severs the kinetochore-microtubule attachment [1, 34, 35] . Consequently, AK-B inhibition retards the repair of incorrect microtubule-kinetochore attachment [32, 34] . Also, it has been observed that both AK-A and B mediate the recruitment of checkpoint proteins to the kinetochore, including Bub1, BubR1, CENP-E, Bub3, Mad1, and Mad2 [36] . Mad2 can directly interact with Cdc20 and inhibit the activation of APC/C [37] . Treatment of cells with AK-B inhibitors caused chromosome alignment problems, spindle checkpoint override and cytokinesis failure [34, 38, 39] . From the above observations and following [22] , it can therefore be reasonably hypothesised that: (i) AK-A inhibition reduces all net transition rates in the state transition framework in Fig. 1b; (ii) AK-B inhibition mediates the fixing of incorrect attachments and therefore affects rates k 4 and k 5 only; (iii) AK-B inhibition reduces the rate of recruitment of checkpoint proteins to the kinetochore and therefore reduces the relevant rate constants k k in (1); (iv) both AK-A and B are involved in the catalytic production of inhibited complexes of Cdc20 and thus affect rate k in (1).
In the model, these hypotheses translate as follows. It is assumed that the transition rate parameters k 1 , k 2 and k 3 are positively correlated to the value of A where A is the relative activity defined above. In lieu of further evidence and adopting a ''simplest first'' approach, this relationship is taken to be linear, i.e., we set k 1 ðAÞ ¼ k 
Temporal evolution of the spindle assembly checkpoint model
First, we outline how the dynamics of the state transition processes are modelled.
(For an alternative, but related method see ref. [40] .) Let hX i i(t) denote the expected mean number of kinetochore units in a state i [ {U, S, ME, C} at time t in any given cell within a large population of genetically identical cells. The temporal evolution of each hX i i is given by the following system of ordinary differential equations (see refs. [21, 22] for a full derivation),
where the parameters k i (A) (i = 1, 2, 3) and k j (A, B) (j = 4, 5) and their dependence on A and B are as detailed above. At the start of prometaphase (denoted here as t = t 0 ), it is assumed that all kinetochores are unattached and thus in the case of humans,
Note from (4), a conservation law can be derived: by adding all equations it follows that
for all t [ t 0 and thus and from (5),
Hence, one of these variables can be omitted and derived directly from the others via (6) . Clearly, the only steady state of system (4) is hX U i = hX ME i = hX S i = 0 and hX C i = 46, where the last value is determined by (5) . This represents the endpoint of the state transition process when all the attachments are of correct type. Moreover, if the activities A and B are constant then system (4) is a linear, constant coefficient system of ODEs and using the initial data (5), a closed form solution for each hX i i can be computed that comprise exponential terms. Thus the solutions of (4), (5) tend (asymptotically) to the endpoint steady state: hX U i(t) decreases monotonically from the initial value of 46 towards zero; hX S i(t) and hX ME i(t) first increase to a maximum value and then monotonically decay to zero and; hX C i(t) increases monotonically, saturating at the value 46. Even if A and B are functions of time (as will be considered later), the dynamics remain essentially unaltered; only the rates of convergence to the individual components of the endpoint steady state are changed (see Fig. 3 ).
The dynamics of the SAC reaction (1) can be modelled using mass action principles. Letting N x (t) denote the total number of molecules of species x [ {e, e * , c * , g * } at time t per cell, then the temporal evolution of these numbers of the checkpoint proteins can be described by a system of ordinary differential equations in which the SAC proteins and the signalling units are the reactant variables. However, the objective here is to construct a model capable of predicting the number of aberrant attachments (syntelic, merotelic or unattached) at the onset of anaphase. Therefore, it is more appropriate for our purposes here to consider the wait signal from incorrectly attached units to behave as a binary switch. (Since it is assumed that both kinetochores within a unit have either all binding sites occupied or available, this is reasonable in any case.) Thus a (nearest) integer representation of the output from system (4) is stored at each time t as IX U (t), IX C (t), IX S (t) and IX ME (t), respectively. (In [40] , a discrete approach is taken to modelling kinetochore attachment where kinetochores are considered to be either attached or unattached.) Recall that the total number of units within any given cell is conserved (and thus one of the variables is redundant). However, it does not hold a priori that the same conservation law holds for the integer representations. This can be circumvented by simply insisting that the integer representations satisfy This integer representation is of particular importance when the values of hX i i, i [ {U, ME, S} are low. As detailed above, a consequence of the averaging procedure used to generate system (4) is that the variables hX i i tend asymptotically to their respective steady state values. Thus, even in the uninhibited case, this would suggest that the cell never proceeds to anaphase. Clearly, within a real cell, there are a finite number of kinetochores, which become correctly attached in a finite time and so it is reasonable to assume that if hX i i \ 0.5, then this represents the case where no attachment of type i exist (see ref. [21] ). Here, the integer representation does this automatically: if hX i i \ 0.5 then IX i = 0. Finally, with all the above points taken into consideration, the evolution of the SAC can be modelled thus:
where v c is cell volume. From system (7) and following similar arguments to those above, it is clear that the total number of molecules is conserved, i.e. N e ðtÞ þ N e Ã ðtÞ þ N c Ã ðtÞ þ N g Ã ðtÞ ¼ N 8t ! t 0 for some constant N and we choose N = 800,000 (see ref. [5] ). At t = t 0 (the start of prometaphase) it is assumed that the concentration of free Cdc20 is zero and as the recruitment process has not yet started, that the concentrations of the inhibited complexes e * and c * are also zero. However, it is assumed that the inhibitory complex g * is not zero (the disassociation of this complex can be viewed as an implicit production of free Cdc20). Thus we set the initial conditions
System (7), (8) forms a nonlinear initial value problem. Even in the case where A and B are constant, no closed form solution of this problem exists. However, as discussed in [21, 22] , the general dynamics of the uninhibited system represent a combination of ''tight inhibition'' of N e up to the point where all kinetochores are correctly attached (IX C = 46) after which a ''fast release'' occurs allowing the N e value to rise rapidly. Inhibition of the activities A and B causes quantitative changes to this combination [22] . Sample simulations are shown in Fig. 3 . Notice that inhibition of AK-A and B induces a delay in achieving all correct attachments.
Modelling a cell population Systems (4) and (7) form a mathematical description of key components in the temporal evolution of the spindle assembly checkpoint. Adding Eq. 2 allows for the consideration of (possibly dynamic) AK inhibition in this checkpoint. We now discuss how these core modelling components can be integrated to analyse the behaviour of a population of cells over a 24 h period during drug treatment.
Normally, within any living organism (or indeed within a cell culture), cells enter mitosis in an almost continuous manner. As a reasonable and computationally manageable approximation to this continual process, we consider series of cell cohorts that enter mitosis every 30 s (and hence a total of 2880 cohorts is considered over the 24 h period). Within each cohort it is assumed that cells are synchronised in the cell cycle. Thus our spindle assembly checkpoint model can be applied to each cohort in turn and is viewed as modelling the behaviour of a representative, or average cell in that cohort. (In the following, only the ratio of damaged and undamaged cohorts is considered, and hence the exact number of cells in each cohort is immaterial for our purposes, other than that each cohort is assumed sufficiently large in order to ensure the validity of the modelling procedures.) Therefore, if this representative cell is healthy or damaged, we assume all cells in the cohort are in a similar state.
Modelling cell abnormalities
A key model output is the definition of a qualitative measure of cell abnormality. As detailed in [5] , it is assumed that 60 % of total Cdc20 (about 480,000 molecules per cell) is sufficient to activate the onset of anaphase. Therefore, we define the time at start of anaphase as:
and thus the length of prometaphase/metaphase as t a -t 0 , where t 0 marks the start of prometaphase. If the spindle assembly checkpoint is not functioning properly, anaphase commences without waiting until all kinetochores are correctly attached. A measure of this deregulation can therefore be directly obtained from the model as the number of aberrant units in a representative cell at the start of anaphase: Parameterisation and numerical methods
The integrated PK-PD model constructed as detailed above was used to investigate the effect of CYC116 in two common laboratory systems: cell culture and mice. Table 2 summarises the parameter values used in the model for these two systems.
A sensitivity analysis revealed that systems (4) and (7) are robust to variation in parameter values provided certain core features are maintained e.g. the fixing time (time taken for all attachments to be correctly made) and time to anaphase in the control case. As discussed in [21] , the core models for the state transition process and the temporal evolution if the SAC are robust to (even quite large) changes to parameter values. Many of the rate constants used in [21] were a synthesis of known data and previously used values. Similarly here, the exact values are less important than the general order.
All simulations were carried out using a fourth order Runge-Kutta method for ODEs, which was implemented using C??. Matlab was used to visualise data produced from C??. A time step size of Dt ¼ 10 À3 was used throughout, which offered a good compromise between computation time and accuracy. As is standard, it was first confirmed that reducing this step size further made no appreciable difference to the qualitative or quantitative output of the model in various test cases. Simulation algorithms for cell culture and mouse model systems are schematically represented in Figs. 4 and 5 , respectively.
A cell culture system: model results
We simulated a typical example of an in vitro experiment of the type considered in [26] . It was discussed there how a variety of cell lines were exposed in vitro to CYC116 and other kinase inhibitors for times varying between 1 and 24 h (as well as doses on sequential days not considered here). Following standard experimental protocols, mitotic defects were detected and quantified using immunofluorecent microscopy. The biomarkers for AK-A and B activity were phosphorylated AK-A and histone H3, respectively as discussed above. In [26] , the range 0-5 lM was considered. For completeness in the model, drug concentrations ranging from 0 to 14 lM were simulated. We assumed that the rate of degradation of CYC116 was sufficiently slow to allow the concentration to be assumed constant throughout a 24 h period. Thus we assumed all cohorts of cells in the model simulation were exposed to the same drug concentration throughout a 24 h period.
Inhibition and aberrant attachments
Equation 2 ensures that a constant drug concentration leads to a constant (inhibited) level of AK-A and AK-B activity. Hence, for a given initial drug dose, all cohorts of cells throughout the simulated 24 h period had identical activities A and B, regardless of when the cohort was modelled as having entered prometaphase and thus responded identically. For any given fixed drug concentration, the measure of abnormality, v was therefore either 0% (normal) or 100% (completely abnormal). The model predicted that the threshold concentration of CYC116 required to reduce (We note that this has yet to be experimentally investigated and therefore represents a hypothesis generated by the model). Figure 6 shows the dose-response of the expected integer number of aberrant units within a representative cell. Each bar also shows the proportion of the three types of kinetochore-microtubule miss-attachments. Up to doses of 0.6 lM, there were no aberrant units, i.e., v = 0 %. At a threshold dose of 0.7 lM, aberrant units started to appear (v = 100 %). As the dose increased, the number of aberrant units increased with an increasing proportion of syntelic attachment and merotelic attachments. At doses more than 1.7 lM, unattached units started to appear. When 0 , which has a period of 24 h (i.e., drug(DT 0 ) = drug(DT 0 ? 1440)). AK activities, which influence parameter values for kinetochore-microtubule attachments and the spindle checkpoint, also change over time associated with drug concentrations drug(DT 0 ). For each drug concentration and the corresponding AK activities, when free Cdc20 concentration (Ne) reaches the threshold value (480,000), time to anaphase, t a , and the number of aberrant units (IX U (t a ), IX ME (t a ), IX S (t a ), and IAU(t a )) are written to an output file the dose reached 8.2 lM, almost all units (44-45 out of 46) within the cell were unattached. The number of aberrant units did not reach 46 even with high doses of CYC116 because even under very strong inhibition, there is a small but non-zero probability of some unattached units (U) transit directly to correctly attached units (C).
Time to anaphase
For ease of notation here and below, we associate the time to anaphase, t a , with the length of prometaphase/metaphase t a -t 0 . This is simply a resetting of time t 0 = 0 for each new cohort. Figure 7 shows the relationship between time to anaphase, t a and CYC116 dose. It is immediately obvious that the model predicts the relationship between these quantities to be nonlinear. For low concentrations, t a was increased-by up to ninefold for doses of around 1lM. The model predicts that anaphase is delayed for doses up to 4.5lM but t a is then reduced below the control time (approximately 40mins) for higher doses. A distinct saturation effect is observed for doses above approximately 8 lM: t a is approximately constant (approx. 10 mins) for all doses above this level. This the behaviour is a result of competing components of the model-the attachment process (4) and the SAC signalling process (7) . If the attachment process is slowed down by inhibition, but the signalling process is still functioning, then the latter detects the presence of incorrect attachments, maintains tight control of N e (free Cdc20) and thus t a is delayed. However, if AK activity is further inhibited by higher doses, then the signalling mechanism also fails, allowing N e to reach threshold and hence triggering anaphase whilst incorrect attachments are still present. The saturation effect at high doses is due to a catastrophic failure of the signalling mechanism (7), which in this case essentially allows the build up of N e to threshold (and hence the triggering of anaphase), at a rate determined by the input of free Cdc20 into the system via the degradation of g * .
A mouse system: model results
We simulated a typical example of an in vivo experiment of the type considered in [26] . Presented there were results from experiments using tumour-bearing mice (P388, leukemia; MV4-11 human leukemia xenograph; NC-H460 NSCLC xenograph) which had been administered CYC116 orally both q.d. and b.i.d. with treatments lasting up to 32 days. Individual doses ranged from 45 mg kg -1 dose to 100 mg kg -1 dose. Efficacy was estimated by measuring tumour volume. 
Pharmacokinetics
At present, the model is not capable of predicting the cumulative effects of AK inhibition as cells pass through multiple cell cycles. Thus we focussed on simulating the effects of dosing regimes over a 24 h period, and only those cells in prometaphase/metaphase were considered. We did however, consider a wider range of dosing regimes than those considered in the experiments detailed above: We viewed a one-compartment model to be sufficient for the purposes of predicting the PK in the simulated in vivo experiment and following standard arguments (see ref. [41] ), the CYC116 concentration (lM) in plasma at time t, following an oral dose given at time t = 0, was computed using the equation
where F is fractional oral availability, D is dose in micromoles per kg body weight, V is the volume of distribution (L kg -1 ), k a (min -1 ) is the rate constant for oral uptake, k e (min -1 ) is the rate constant for elimination, and time t is in minutes. The parameter values used in the model simulations are given in Table 3 . These values were estimated by fitting both IV data and PO data (Cyclacel Ltd., unpublished) as shown in Fig. 8 . By minimizing the least square error of 3 repeats to appropriate functional forms, the data shown in Fig. 8a were used to compute the volume of distribution, V, and the rate constant of elimination, k e . Figures 8b, c and d were used to compute k a , the rate constant of uptake. The value of oral availability, F = 0.343 is standardly used for CYC116 by Cyclacel Ltd.. Figure 9 shows time evolution curves of plasma CYC116 concentrations for the four different drug schedule treatments with total oral dose equivalent to 100 mg kg -1 . The curves are qualitatively similar for other total doses. Total oral dose was varied from 0 to 100 mg -1 kg and the effects on time to anaphase and attachment type were recorded.
As the plasma concentration given by (10) varies with time, the AK activities, A and B, associated with any given cohort of cells will also vary with time. Moreover, as each new cohort progresses through the attachment process, it is exposed to a different drug concentration profile (see Fig. 5 ). 
Inhibition and aberrant attachments
The reaction of one generation of tumour cells within a mouse to a number of different dose regimes detailed below, was predicted using the model (4), (7) . Figure 10 shows the dose-response of the measure of abnormality v calculated by Eq. (9) for the four treatments with the total oral doses ranging from 0 to 100 mg kg -1 . Figure 10b shows the zoomed in view of Fig. 10a for the total oral doses from 1 to 20 mg kg -1 . Aberrant units were induced (v [ 0) for total oral doses of 4 mg kg -1 and above, 7 mg kg -1 and above, 11 mg kg -1 and above and 14 mg kg -1 and above for treatments 1-4, respectively. A link between the appearance of aberrant units and peak drug concentration is shown in Fig. 11 the first data point that lies above this intersection corresponds to 4 mg kg -1 . Similar correspondence holds for all other treatments. In each case these were exactly the plasma concentration thresholds required to force v [ 0.
Level of damage of aberrant attachments
As for the in vitro case, we also considered the level of damage induced by calculating the average number of aberrant units among all damaged cohorts i.e. those with representative cells with IAU(t a ) [ 0. Figure 12 shows the relationship between total oral dose of CYC116 and average number of aberrant units, IAU(t a ). Each bar, corresponding to a total oral dose of CYC116, also shows the proportion of aberrant attachment types (unattached, syntelic, and merotelic). For treatment 1, once total oral dose exceeds 50 mg kg -1 . The majority of microtubule-kinetochore units are miss-attached (Fig. 12a) . Moreover, the profile for representative cells from damaged cohorts, matches the profile for the whole generation as shown in of aberrant attachments. Increasing the total oral dose increased both the proportion of damaged cohorts and the average damage to those cohorts. Figure 12b shows the results for treatment 2. Almost half of microtubule-kinetochore units are missattached if the total oral dose exceeds 100 mg kg -1 . Again, the profile for representative cells from damaged cohorts matches the profile for the whole generation as shown in Fig. 10 with the same interpretation as for treatment 1. Finally, Fig. 12c and d show results for treatments 3 and 4, respectively. No missattachments were predicted for total oral doses of CYC116 below 10lM.
Time to anaphase Figure 13 shows the predicted relationship between total oral dose in 24 h and the mean time to anaphase over all cohorts. For each treatment, the maximum t a increased with total oral dose, whilst minimum t a decreased with total oral dose. The mean and standard deviation increased to a lesser degree with total oral dose but as with all cases, a marked saturation effect was observed (clearly seen here for treatment 1 and 2 but similar behaviour was also observed for treatments 3 and 4 when the dose range was extended-data not shown). Moreover, for each fixed total oral dose across the considered range, the model predicted that the mean and minimum t a increased with dose frequency whilst the maximum t a decreased with dose frequency although this latter behaviour was less distinct and displayed a strong saturation effect-for higher total oral doses, the maximum t a was approximately the same for all treatments. These behaviours were somewhat unexpected predictions of the model, but can be explained as follows. For each treatment, increasing total oral dose increased both the peak plasma concentration and the time over which the plasma concentration varied through a significant range. Thus for high total doses, a few cohorts were exposed to high peak plasma concentrations of CYC116 throughout their time in the simulation and hence returned low values of t a (see the arguments above regarding t a for the in vitro case). The range of plasma concentrations ensures that at least one cohort was exposed to the critical low drug concentration required to extend the fixing process but not compromise the wait signal (see again the discussions above). For a given total oral dose, increasing dose frequency had the effect of reducing peak plasma concentrations resulting in an increase to the minimum t a recorded. On the other hand, increasing dose frequency also ''levelled out'' the plasma concentration and therefore the plasma concentration was at the critical (low) value required to induce long delays in anaphase for only brief periods of time. Thus the model predicted that any given cohort was exposed to this critical plasma concentration for at most only a small proportion of its time in metaphase. 
Discussion
In this paper, we investigated the effects of an Aurora kinase inhibitor on the spindle assembly checkpoint by constructing an integrated PK-PD model of sufficient detail to capture the main features of this process. Although the model is sufficiently general to be applicable to a wide class of AK inhibitors, the mixed affinity inhibitor CYC116 was the main focus of this study. An immediate conclusion from the model is that a full understanding of the efficacy of this, and other similar inhibitors can only be obtained by linking pharmacokinetic and pharmacodynamic processes.
Two typical experimental systems were simulated using the PK-PD model: cell culture and tumour bearing mice. In both cases, the model predicted that inhibition of Aurora kinase activity by CYC116 induced the appearance of aberrant kinetochore-microtubule attachments at anaphase. By simulating the cell culture system, a CYC116 concentration of approximately 0.7 lM was identified as the minimum required to cause aberrant kinetochore-microtubule attachments. By simulating the mouse system, four key properties of drug scheduling and concomitant PK-PD emerged: (i) There was a threshold peak plasma concentration (approximately 0.7 lM-similar threshold to the in vitro case) below which no aberrant units were generated; (ii) For treatments that induced peak concentrations above this threshold, the maximum value of the concentration determined the average number of damaged units within each damaged cohort (Fig. 12) ; (iii) For treatments that induced peak concentrations above the threshold, the total amount of time for which the plasma concentration was maintained above this threshold determined the proportion of damaged cohorts (Figs. 10 and 14) ; (iv) There is a saturation effect on abnormality of the cell population for high oral doses corresponding to the saturation effect of the total amount of time for which the plasma concentration was maintained above the threshold (cf. Figs. 10 and 14) . These results are broadly in line with recent experimental studies of CYC116, in particular the existence of a threshold and the relationship between peak plasma concentration and cell damage [26, 27] . It is noted that the 4 times a day dosing schedule considered here would be difficult to administer in the laboratory situation. However, it may be of benefit to consider such regimes for humans and thus was studied here in order to generate theoretical predictions beyond those obtainable by standard experimental procedures.
For both in vitro and in vivo experimental systems, the model predicted that the time to anaphase (the length of prometaphase/metaphase) was related to CYC116 concentration in a complex, non-linear manner (Figs. 7 and 13) . A marked increase in time to anaphase was induced at low concentrations but time to anaphase decreased for high concentrations to a value well below the control time of approximately 40 mins. A strong saturation effect at high doses was observed. In the in vivo simulations, the maximum, minimum and mean time to anaphase were related to both peak plasma concentration for a given total oral dose of CYC116 and dose frequency. Again, there was a saturation effect at high doses. These results were qualitatively unaffected by small variation in parameter values and thus we are confident that they represent a robust model prediction.
The results detailed above suggest that Aurora kinase inhibitors such as CYC116 are potentially efficacious in two ways: (1) They could be used to induce aberrant attachments at the start of anaphase. These defects may result in the generation of polyploidy as observed experimentally [26, 27, 42] and eventually lead to cell death of fast replicating cells and potentially those with a greater sensitivity to AK inhibition. (2) They could be used to ''arrest'' and therefore ''stack'' fast replicating cells in prometaphase by extending the time to anaphase thereby inducing secondary effects and/or allowing other drugs, which are active during that part of the cell cycle, to be more effective.
It is not clear if the number of aberrantly attached chromosomes in a given cell is critical to cell fate. If a high number of aberrant attachments is necessary to cause cell death or cell cycle arrest at the next checkpoint, then the model predicts that administering a single high level oral dose is the most effective treatment, for any given generation of cells. If a small number of aberrantly attached chromosomes in a cell is sufficient to induce cell death or cell cycle arrest at the next checkpoint, then the model predicts that the best regime to follow is to expose each generation of cells to the minimum drug concentration, whose peak concentration is more than 0.7 lM but to maintain this super-threshold concentration for as long as possible throughout the treatment by, for example, regular dosing. Fig. 14 Dose-response relationship of the total time length (within 24 h) for which CYC116 plasma concentration was maintained above the threshold concentration (0.7 lM) for each of the treatments 1-4 and over a range of total oral doses Finally, the model predicts that CYC116 exhibits saturation behaviour: above a certain drug concentration level, the spindle assembly checkpoint in badly damaged cells was completely overridden and cells progressed to anaphase with almost all chromosomes miss-alined. Moreover, the time to anaphase saturated to a subcontrol level for high doses. (Moreover still, if the aim was to use CYC116 to extend the time to anaphase, then this is most readily achieved for low doses.) Hence, the model predicts that there is no need to administer higher doses than the saturation level (around 100 mg kg -1 day -1 ). Given that high drug doses are normally associated with unwanted off-target effects, this may be a useful result and one that certainly requires further investigation. These model predictions invite experimental investigation and verification, but if they hold true may have important consequences for the design of drug trials and ultimately, in the longer term the management of drug administration in patients.
